Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer.
about
Synchronous uterine carcinosarcoma and contralateral breast cancer after tamoxifen therapy: a case reportRelationship between radiation exposure and risk of second primary cancers among atomic bomb survivors.Estrogen receptor status in relation to risk of contralateral breast cancer-a population-based cohort study."Iron-saturated" bovine lactoferrin improves the chemotherapeutic effects of tamoxifen in the treatment of basal-like breast cancer in mice.Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancerStemness of the hybrid Epithelial/Mesenchymal State in Breast Cancer and Its Association with Poor Survival.Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer.The Values of Combined and Sub-Stratified Imaging Scores with Ultrasonography and Mammography in Breast Cancer Subtypes.Use of Antihypertensive Medications Not Associated with Risk of Contralateral Breast Cancer among Women Diagnosed with Estrogen Receptor-Positive Invasive Breast Cancer.Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study.Variation in the risk of radiation-related contralateral breast cancer by histology and estrogen receptor expression in SEERAssociation of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.Second malignancies after breast cancer: The impact of adjuvant therapy.Risk of second breast cancer according to estrogen receptor status and family history.Patterns of Occurrence and Outcomes of Contralateral Breast Cancer: Analysis of SEER Data.
P2860
Q34121698-9892A19B-9D75-479C-9335-EB53ADBAD747Q34139683-75048441-A3F1-418D-9444-E309BCEAE88AQ34441602-F672CB65-677F-4FF9-AA51-6579299F7CC8Q34508653-025B2F5E-4195-4A15-A938-547011D69CEBQ35596736-19A3A2BD-FA67-4F66-BAA1-03AF17F7452FQ35644828-818E0846-4EF6-4567-BCFC-E50E358720F9Q35677929-7D0636C6-E109-45B7-9441-07EEE004822BQ35874075-4297944A-5458-4836-86AE-D541CC453CE1Q36029475-FFD83561-04EC-45A1-8605-0879C6B30153Q37085141-726DE241-CF8E-4FDD-A85A-56B7664D0643Q37379588-828E50A2-FBE4-46E4-8088-48C8CB5BC0CAQ39315948-7FD8DF12-FACA-49CD-A318-86C46764D3F7Q42332612-8077BD9B-AD4B-4BBE-9979-C178FE058456Q44558762-21906E3F-B67F-4BBA-BFB0-B94FCC21E121Q55515741-94A58D2D-DDEF-48CC-AE14-48E5FA728A98
P2860
Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adjuvant hormonal therapy for ...... f contralateral breast cancer.
@en
Adjuvant hormonal therapy for ...... f contralateral breast cancer.
@nl
type
label
Adjuvant hormonal therapy for ...... f contralateral breast cancer.
@en
Adjuvant hormonal therapy for ...... f contralateral breast cancer.
@nl
prefLabel
Adjuvant hormonal therapy for ...... f contralateral breast cancer.
@en
Adjuvant hormonal therapy for ...... f contralateral breast cancer.
@nl
P2093
P2860
P1433
P1476
Adjuvant hormonal therapy for ...... f contralateral breast cancer.
@en
P2093
Christopher I Li
Janet R Daling
Kathleen E Malone
Mei-Tzu C Tang
Peggy L Porter
P2860
P304
P356
10.1158/0008-5472.CAN-09-1355
P407
P577
2009-08-25T00:00:00Z